NEWARK, DE--(Marketwired - Mar 4, 2014) - iBio, Inc. (
iBio management is scheduled to present at 5:30 p.m. Pacific time on Monday, March 10, with one-on-one meetings held throughout the day.
Management will discuss its new subsidiary, iBio Brazil, facilitating entry of biosimilar therapeutics into the rapidly growing Brazilian market. The company's proprietary products are produced from plants rather than animal sources, with this providing a number of potential safety, performance and cost advantages.
For more information about the conference or to schedule a one-on-one meeting with iBio management, please contact your ROTH representative at 1-800-933-6830 or via e-mail at email@example.com.
To learn more about ROTH Capital Partners and the 26th Annual ROTH Conference, please visit www.roth.com.
About iBio, Inc.
iBio develops and offers proprietary products and product licenses, based on its proprietary iBioLaunch and iBioModulator™ platforms, providing collaborators full support for turn-key implementation of its technology for protein therapeutics and vaccines. In Brazil, iBio has been collaborating with Oswaldo Cruz Foundation (Fiocruz) and Fraunhofer Center for Molecular Biotechnology since 2011 to develop a recombinant yellow fever vaccine based upon iBio technology.
The iBioLaunch platform is a proprietary, transformative technology for development and production of biologics using transient gene expression in unmodified green plants. The iBioModulator platform is complementary to the iBioLaunch platform and designed to significantly improve vaccine products with both higher potency and greater duration of effect. The iBioModulator platform can be used with any recombinant expression technology for vaccine development and production. Further information is available at: www.ibioinc.com.
Liolios Group, Inc.